Magainin-2 Research: What 530 Studies Show (2026) | RetatrutideCompare

Magainin-2 — 530 studies indexed on PubMed. Forms toroidal pores in microbial membranes, causing rapid lysis of bacteria, fungi, and protozoa. Half-life: Minutes (rapidly degraded systemically). FDA status: Not FDA-approved (Pexiganan, a magainin analog, failed Phase 3).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Magainin-2?

There are approximately 530 studies indexed on PubMed that mention Magainin-2 (MAG-2), based on a search last updated 2026-06-18.

Is Magainin-2 FDA-approved?

FDA status: Not FDA-approved (Pexiganan, a magainin analog, failed Phase 3).

How does Magainin-2 work?

Forms toroidal pores in microbial membranes, causing rapid lysis of bacteria, fungi, and protozoa.

Reference facts

Also known as: MAG-2
Category: Antimicrobial
Mechanism of action: Forms toroidal pores in microbial membranes, causing rapid lysis of bacteria, fungi, and protozoa.
Targets: Microbial membranes
Indications under research or approved: Research scaffold for antimicrobial peptide development
Regulatory status (reference entry): Not FDA-approved (Pexiganan, a magainin analog, failed Phase 3)
Half-life: Minutes (rapidly degraded systemically)
Sequence: GIGKFLHSAKKFGKAFVGEIMNS
Sequence notes: 23-residue cationic α-helical peptide isolated from the skin of the African clawed frog (Xenopus laevis).
Molecular weight (Da): 2466
PDB accession: 2MAG
First reported: 1987
Origin: Discovered by Michael Zasloff at NIH.

Primary References

Zasloff, PNAS 1987 (Magainin discovery)

Explore research articles about Magainin-2

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.